Treatment for recurrent ovarian cancer-at first relapse.
about
Luteinising hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancerLuteinising hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancerAntibody-based immunotherapy for ovarian cancer: where are we at?Loss of PFKFB4 induces cell death in mitotically arrested ovarian cancer cellsRandomized reverse marker strategy design for prospective biomarker validationA phase 2 trial of flavopiridol (Alvocidib) and cisplatin in platin-resistant ovarian and primary peritoneal carcinoma: MC0261Identification of the IGF1/PI3K/NF κB/ERK gene signalling networks associated with chemotherapy resistance and treatment response in high-grade serous epithelial ovarian cancerTargeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies.In vitro enrichment of ovarian cancer tumor-initiating cellsA rare case of recurrent ovarian cancer presenting as a round ligament metastasisVascular endothelial growth factor A as predictive marker for mTOR inhibition in relapsing high-grade serous ovarian cancerPrognostic factors modifying the treatment-free interval in recurrent ovarian cancer.Left inguinal adenopathy two years after cytoreductive surgery: a rare sign of recurrence.Anti-ovarian tumor response of donor peripheral blood mononuclear cells is due to infiltrating cytotoxic NK cellsThe optimal time for surgery in women with serous ovarian cancer.Circulating tumor cell enrichment based on physical properties.Follow-up of patients who are clinically disease-free after primary treatment for fallopian tube, primary peritoneal, or epithelial ovarian cancer: a Program in Evidence-Based Care guideline adaptation.Phenotypic modifications in ovarian cancer stem cells following Paclitaxel treatmentCirculating tumor cells: advances in isolation and analysis, and challenges for clinical applications.Advancing cancer patient care by integrating circulating tumor cell technology to understand the spatial and temporal dynamics of cancer.CT Perfusion as an Early Biomarker of Treatment Efficacy in Advanced Ovarian Cancer: An ACRIN and GOG Study.Nanoscale Coordination Polymers Codeliver Chemotherapeutics and siRNAs to Eradicate Tumors of Cisplatin-Resistant Ovarian Cancer.NFκB Promotes Ovarian Tumorigenesis via Classical Pathways That Support Proliferative Cancer Cells and Alternative Pathways That Support ALDH+ Cancer Stem-like Cells.Therapeutic Effect of α-Emitting 224Ra-Labeled Calcium Carbonate Microparticles in Mice with Intraperitoneal Ovarian Cancer.Effectiveness of low-dose oral etoposide treatment in patients with recurrent and platinum-resistant epithelial ovarian cancer.Cisplatin-induced ERK1/2 activity promotes G1 to S phase progression which leads to chemoresistance of ovarian cancer cells.Proof-of-Concept of Polymeric Sol-Gels in Multi-Drug Delivery and Intraoperative Image-Guided Surgery for Peritoneal Ovarian Cancer
P2860
Q24193930-B88265C2-2E5A-43B3-9F17-4EAC1F5C9710Q26471403-D26659E3-9B67-4D96-AF98-F6C23604B6D8Q27000514-06EBEAD4-1ABB-443A-9270-06C186951D63Q33566765-CAE226AA-E68E-4CE1-A8A8-5EC878DEEF43Q33934952-94890C7D-2A78-4155-A483-1DB02471B461Q34023223-B1A327D8-A05F-4013-8598-6C8D84C92D46Q35044404-B5F2D892-01F8-4E6F-9A4F-15346A25FA03Q35088311-B278589B-88E9-42CB-A629-59E75ADCB629Q35162308-81D91563-D762-4CBE-A049-41CF6EB4D812Q35576622-8312975B-D177-4F12-92A0-56ABA8D27399Q35992948-75302B16-E3EE-4762-95A6-E34F18B4D106Q36240562-1727D6A3-F8B5-4398-B7E3-81B6E0DE6987Q36613813-CAB591FA-1495-41C1-B9EA-5F9D3A35F9F5Q36916476-10FAC656-CB7F-4EC5-BA08-6CA7178954A6Q37127385-C1CC2559-126C-4062-B0BD-EABBCCA618CCQ37315616-1A485DAD-429D-48F8-A4D1-AB370919E10CQ37367890-084D8E62-AC53-4094-894C-EF313858E343Q37481128-CCF3E68C-13EA-48E3-89F7-97C0A7919956Q37626062-7DF543DE-E971-40E2-A715-29DED1296341Q39133502-380383E6-A28F-4B18-A820-7F0B27AD6719Q46085386-4A6278F9-A07E-4525-BFC5-BBC35DB53518Q46940314-4999EF76-A998-4681-B782-F1D1FA6D802DQ47598471-308A96B1-FF9C-4DC4-A315-E428BA941047Q49372551-8319BAD0-1CB2-417F-9B6C-90E182949073Q53746774-15294C62-2CAA-475E-8DA0-6482C8D444F9Q55122746-96E44D43-FB97-4731-894D-47E24E203912Q57273260-1B434924-851E-4558-BEDE-7B9D5C97A972
P2860
Treatment for recurrent ovarian cancer-at first relapse.
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Treatment for recurrent ovarian cancer-at first relapse.
@ast
Treatment for recurrent ovarian cancer-at first relapse.
@en
Treatment for recurrent ovarian cancer-at first relapse.
@nl
type
label
Treatment for recurrent ovarian cancer-at first relapse.
@ast
Treatment for recurrent ovarian cancer-at first relapse.
@en
Treatment for recurrent ovarian cancer-at first relapse.
@nl
prefLabel
Treatment for recurrent ovarian cancer-at first relapse.
@ast
Treatment for recurrent ovarian cancer-at first relapse.
@en
Treatment for recurrent ovarian cancer-at first relapse.
@nl
P2860
P356
P1433
P1476
Treatment for recurrent ovarian cancer-at first relapse.
@en
P2093
Kimio Ushijima
P2860
P304
P356
10.1155/2010/497429
P577
2009-12-24T00:00:00Z